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Introduction
The incidence of gastric cancer varies between regions of 
the world, with more cases in eastern Asia [1]. Recently, 
the data of the National Cancer Institute’s Surveillance 
Epidemiology and End Results (SEER) program showed a 
significant rising incidence of EOGC (early- onset gastric 
cancer) in both female and male patients, but with a con-
spicuous female gender predominance [2, 3]. EOGC is a 
subtype of gastric cancer in patients younger than 45 years 
old. Approximately 10–20% of young gastric cancer patients 
have a positive family history [4], some of whom present 
with inherited gastric cancer predisposition syndromes. 
Although the underlying genetic events are not always 
known, EOGC may show CDH1 gene germline mutations 
[5–7], encoding an aberrant form of E- cadherin, a cardinal 
feature of hereditary diffuse gastric cancer (HDGC), as 
recently reviewed by Carneiro et al. [7]. However, CDH1 
may partially explain EOGC [8], and more studies [9, 10] 
would suggest p53 as a candidate mutated gene in EOGC.
The p53 gene is present at very low levels in normal 
cells and involved in many cellular functions, including 
the regulation of apoptosis, cell proliferation, angiogenesis, 
and cell cycle [11, 12]. A mutation of the p53 gene is 
ORIGINAL RESEARCH
Expression profile of E- cadherin, estrogen receptors,  
and P53 in early- onset gastric cancers
Fan Zhou1,*, Yuanyuan Xu1,*, Jiong Shi2, Xing Lan3, Xiaoping Zou1, Lei Wang1 & Qin Huang2,4
1Department of Gastroenterology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, Jiangsu, China
2Department of Pathology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, Jiangsu, China
3Xuzhou Medical University, Xuzhou, Jiangsu, China
4Department of Pathology, VA Boston Healthcare System and Harvard Medical School, Boston, Massachusetts
© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.  
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, 
distribution and reproduction in any medium, provided the original work is properly cited.
Keywords
Early-onset gastric cancer (EOGC), E-cadherin, 
estrogen receptors (ERs), P53
Correspondence
Lei Wang, Drum Tower Hospital Affiliated to 
Nanjing University Medical School, Nanjing, 
Jiangsu, China.  
Tel: 13851579216; Fax: 86 25-83304616;  
E-mail: wang128zb@gmail.com
and
Qin Huang, Department of Pathology, VA 
Boston Healthcare System and Harvard 
Medical School, Boston, MA.  
Tel: 13505185265; Fax: 86 25-831106666;  
E-mail: qinhuang0122@hotmail.com
Funding Information
This work was supported by Nanjing Scientific 
Technology and Development Project 
201402032 (Nanjing, China).
Received: 4 June 2016; Revised: 26 August 
2016; Accepted: 4 September 2016
Cancer Medicine 2016, 5(12):3403–3411  
doi: 10.1002/cam4.931
*Fan Zhou and Yuanyuan Xu contributed 
equally to this work.
Abstract
Early- onset gastric cancer (EOGC) is predominant in females, diffuse histology, 
and hereditary pattern. Germline mutation of CDH1 and p53 has been reported 
previously and female dominance was speculated to be associated with estrogen 
and its receptors. Expression of E- cadherin, estrogen receptor α (ERα), estrogen 
receptor β (ERβ), and p53 in EOGC remains unclear, which was the focus of 
this study, to assess clinical significance of their expression in EOGC. The ex-
pression of E- cadherin, ERα, ERβ, and p53 in tumors and normal tissues from 
surgically resected EOGCs was assessed by immunohistochemistry (n = 139) 
and Western blot (n = 7) methods, respectively. The expression in tumor tis-
sues was significantly higher for ERα, ERβ, and p53, but lower for E- cadherin, 
compared to uninvolved mucosa. Positive staining of ERβ and p53 was more 
frequently observed in younger patients with advanced TNM stages. For 
 E- cadherin, significant correlation was observed between the immunopositivity 
and TNM stages IA+IB. P53- negative patients had significantly better outcomes 
than p53- positive patients. Significant association between expression of 
 E- cadherin and histologic types was found in familial, but not in sporadic, 
EOGC. In conclusion, our results demonstrated E- cadherin may have a role in 
initiation of EOGC and positive ERβ and p53 expression may partially explained 
early- onset and tumor progression of EOGC.
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frequently observed during the development of numerous 
human malignancies [13, 14]. Overexpression of p53 has 
been shown in numerous human tumors, and high levels 
of p53 protein have been correlated with malignant pro-
gression in colorectal tumors and lung carcinoma in 
advanced stages. In addition, overexpression of p53 has 
been shown to be independently related to poor prog-
nosis in breast carcinoma [15, 16]. However, few studies 
have been conducted to assess p53 expression in EOGC 
[13].
In terms of gender differences in EOGC, most studies 
attributed the female predominance to possible roles of 
estrogen receptors in the pathogenesis of EOGC [17]. 
Since Tokunaga et al. [18] first reported estrogen recep-
tor (ER) α expression in gastric cancer, a series of 
studies have been focused on the role of ERα in gastric 
cancer progression. In 1996, two forms of ERs, ERα 
and ERβ, were identified, but only ERβ, not ERα, was 
expressed in gastric cancer [19], whereas others show 
the evidence of expression for both ERα and ERβ recep-
tor genes [19–21]. Recently, a large Chinese cohort study 
[21] shows the presence of ERα, ERβ, progesterone 
receptor (PR), and androgen receptor (AR) in both 
gastric cancer and noncancer tissues with predominant 
expression in ERβ and no prognostic significance for 
the expression.
Herein in this study, we investigated the expression and 
clinicopathological significance of E- cadherin, p53 in EOGC, 
and explored the role of ERα and ERβ in EOGC progres-
sion in young Chinese patients treated at a single high- volume 
hospital in China. To our knowledge, this study was the 
largest sample study regarding the predictive significance of 
E- cadherin, p53, and estrogen receptors in EOGC.
Materials and Methods
Patients and tissue samples
EOGC patients younger than 40 years old at Nanjing 
Drum Tower Hospital, Jiangsu, China, from Jan 2004 to 
Dec 2014 were enrolled. Patients without enough tissue 
sample or necessary clinicopathological information, or 
loss to follow- up were excluded from the study. The 
study cohort was part of our previous study [22]. The 
paired formalin- fixed paraffin- embedded tissue blocks 
(tumor and nontumor in the same case) were retrieved 
and recut for immunohistochemistry. Proteins were 
extracted in frozen matched tumor and nontumor tissues 
from our biobank at this hospital. The study protocol 
was approved by the Medical Ethics Committee of the 
Nanjing Drum Tower Hospital. Informed consent was 
obtained from all individual participants included in this 
study.
Immunohistochemistry
Immunohistochemical (IHC) analysis for E- cadherin, ERα, 
ERβ, and p53 expression was performed on formalin- fixed, 
paraffin- embedded sections of surgical specimens. Briefly, 
sections were deparaffinized in xylene and rehydrated in 
gradient ethanol solutions up to distilled water. Endogenous 
peroxidase activity was blocked by 0.3% H2O2 in methanol 
for 20 min. The slides were immersed in 10 mM citric 
buffer (pH 6.0) with heating for 15 min for antigen 
retrieval. Nonspecific binding sites were blocked with 10% 
normal goat serum for 10 min. Then, sections were incu-
bated in a humidified chamber overnight with primary 
antibody (listed as in Table S1). Immunostaining was 
visualized with DAB and hematoxylin counterstain.
Two experienced pathologists (JS, QH) independently 
reviewed the expression of the four antibodies without 
the knowledge of patients’ clinicopathological parameters. 
The scoring for E- cadherin and ERβ (expressed at a high 
level) was based on the area intensity score method (AIS) 
[23]. Intensity scores from 0 to 3, respectively, represented 
absent, weak, moderate, and strong positive immunostain-
ing. The area scores from 0 to 4 were estimated for the 
proportion of positively stained neoplastic cells in the entire 
tumor on the slide, as 0 = <5%, 1 = 5–24%, 2 = 25–49%, 
3 = 50–74%, and 4 = ≥75%, respectively. The overall AIS 
score was obtained by multiplication. For ERα and p53 
immunostaining, a negative stain was defined as less than 
10% positive neoplastic cells on the slide; otherwise the 
stain was classified to be positive. Overexpression of p53 
generally reflects an underlying mutation(s) in the p53 
gene, and manifests as positive immunostaining.
Western blot analysis
Target tissues were homogenized in the RIPA lysis buffer. 
The supernatant was used for Western blot analysis. Protein 
concentrations were determined using the BCA assay regent. 
Thirty to sixty micrograms of protein lysates were sepa-
rated on 6–12% sodium dodecyl sulfate- polyacrylamide 
gels and then transferred to the PVDF membranes 
(Millipore). TBST (TBS and 0.1% Tween-20) containing 
5% nonfat milk or bovine serum albumin was used to 
block nonspecific binding for 2 h at room temperature. 
Then, the membranes were incubated with the primary 
antibodies against ERα, ERβ, E- cadherin, and p53 (detailed 
information is shown in Table S1). The membranes were 
rinsed three times with TBST for 10 min and reincubated 
for 1 h at room temperature in blocking buffer with each 
HRP- conjugated secondary antibody (1:5000), and then 
washed three times for 10 min each. Signals generated 
by enhanced chemiluminescence (Millipore) were recorded 
with a CCD camera (CLINX, Shanghai).
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Statistical analysis
Difference in expression of E- cadherin, estrogen receptors, 
and p53 between gastric tumors and corresponding uninvolved 
mucosal tissues was compared by the Students’ t test or 
Wilcoxon matched- pairs signed- rank test where appropriate. 
Correlations were computed using the Spearman rank test. 
The associations between expression of E- cadherin, estrogen 
receptors, and p53 and clinicopathological characteristics were 
analyzed using the Chi- square test. The probability of survival 
was estimated by Kaplan–Meier method with a log- rank test. 
All P values were two sided and considered statistically sig-
nificant if less than 0.05. Statistical analyses were performed 
by the SPSS 22.0 for Windows (SPSS, Chicago, IL).
Results
Protein expression
By immunohistochemistry performed in 139 EOGC tumors, 
expression of E- cadherin was absent in 36 (25.9%), aber-
rant in 43 (30.9%), and normal in 60 (43.2%) patients, 
significantly lower than those (2.2%, 18.7%, and 79.1%, 
respectively) in uninvolved mucosal tissue (P < 0.01) (Fig. 1, 
Table 1). In contrast, the expression of ERα (69, 49.6%), 
ERβ (122, 72.2%), and p53 (42, 33.8%) in tumor tissues 
was significantly higher than those (2.2%, 60.3%, and 4.3% 
for ERα, ERβ, and p53, respectively, detailed data for nor-
mal mucosal not shown) in uninvolved mucosal tissues 
(P < 0.01). In terms of location, staining of E- cadherin 
and p53 is consistent with previous studies, membranous 
and nuclei expression was demonstrated. Nuclei staining 
with anti- ERα antibody was seen. While for ERβ, EOGC 
was stained in both cytoplasmic and nuclei.
Western blotting in seven paired EOGC and uninvolved 
mucosal tissues showed the patterns of changes similar 
to those by immunohistochemistry (Fig. 2). Due to p53 
mutation in gastric cancer, those mutated cases showed 
no signal in western blot.
Correlation with clinicopathological 
characteristics
As shown in Table 1, for E- cadherin, significant correla-
tions were observed between the positive expression and 
TNM stages at IA+IB (P = 0.017). And interestingly, absent 
E- cadherin expression is significantly associated with lower 
lymphovascular invasion (LVI) (P = 0.007). Importantly, 
protein expression of ERβ and p53 was significantly associ-
ated with age and TNM stage, respectively. Positive staining 
of ERβ and p53 was significantly more frequently observed 
in younger patients with advanced TNM stages (P < 0.01). 
P53 expression is also significantly related to LVI, perineural 
Figure 1. Immunostaining and analysis result of E- cadherin, ERα, ERβ, and P53 in Early- Onset Gastric Cancers and Corresponding Adjacent Normal 
Tissues. DGC, diffuse gastric cancer; IGC, intestinal gastric cancer.
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invasion (PNI), and lymph node metastasis (P < 0.001). 
No significant associations were found between expression 
of ERα and clinicopathological features.
Prognostic value
In all 139 patients with postresection survival informa-
tion, expression of E- cadherin, ERα, ERβ, and p53 was 
analyzed for prognostic values by the Kaplan–Meier 
method. P53- negative patients had a significantly better 
outcome than p53- positive patients (P = 0.005; Fig. 3D). 
However, expression of E- cadherin, ERα, and ERβ showed 
no prognostic values in EOGC patients (Fig. 3A, B, and 
C). Univariate Cox regression (Table 2) showed that higher 
CA 72- 4, CA 125, and CA 19- 9 level, larger tumor size, 
positive resection margin, LVI, PNI, advanced staging, 
Figure 2. Western blot of E- cadherin, ERα, ERβ, and P53 in Seven Paired Early- Onset Gastric Cancers and Corresponding Adjacent Normal Tissues. 
por, poorly cohesive carcinoma; lympho, lymphoepithelioma- like gastric carcinoma due to EBV infection; sig, signet ring carcinoma.
E-cadherin
actin
p53
ERα
ERβ
T NT T NT T NT T NT T NT T NT T NT
(por) (mixed) (lympho) (por) (por) (sig) (por)
(Case1) (Case2) (Case3) (Case4) (Case5) (Case6) (Case7)
130 KD
42 KD
53 KD
65 KD
55 KD
Figure 3. Kaplan–Meier Curve according to (A) E- cadherin, (B) ERα, (C) ERβ, and (D) P53 immunostaining (log- rank test).
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and positive p53 expression were related with worse prog-
nosis of EOGC. While for multivariate analysis, only CA 
72–4 (RR: 4.622, 95% CI: 1.487–14.369, P = 0.008), larger 
tumor size (RR: 1.139, 95% CI: 1.000–1.296, P = 0.05), 
positive resection margin (RR: 5.718, 95% CI: 1.797–
18.189, P = 0.003), and stage IV (RR: 20.119, 95% CI: 
1.486–272.465, P = 0.024) are independent prognostic 
factors in EOGC.
Comparison in expression between tumor 
and uninvolved mucosal tissues
Table 3 shows the Spearman correlations in expression 
of E- cadherin, ERα, ERβ, and p53 between cancer and 
adjacent uninvolved tissues. Significant correlation was 
identified for expression of only E- cadherin but not ERα, 
ERβ, and p53. However, the correlation coefficients of 
E- cadherin expression were so small (r = 0.261) that the 
correlation was extremely weak.
Expression in diffuse and intestinal familiar 
and sporadic gastric cancers
As shown in Table 4, expression of E- cadherin was sig-
nificantly more frequent in intestinal and diffuse mixed 
EOGC tumors of familiar, (P < 0.05), but not sporadic 
EOGC cases. No significant associations were found 
between expression of ERα, ERβ, and p53 and different 
histology types of EOGC.
Discussion
Our study reveals that expression of E- cadherin, estrogen 
receptors, and p53 is significantly altered in EOGC. As 
expected, expression of E- cadherin was decreased in the 
diffuse- type familial EOGCs, whereas positive ERβ and 
p53 expression correlated with younger age and advanced 
TNM stages in EOGC, which has not been described 
previously. Independent prognostic factors in EOGC were 
higher CA 72–4 level, larger tumor size, positive resection 
margin, and stage IV cancer.
Although decreased expression of E- cadherin is known 
in the diffuse- type gastric cancer in general, aberrant 
expression of this gene is widely present in EOGC regard-
less of histological type [24], but also correlated significantly 
with the diffuse and mixed types in the familial gastric 
cancer (FGC) [25], suggesting a role of E- cadherin in 
FGC tumorigenesis. We showed that E- cadherin expres-
sion was not associated with gender, age, family history 
of cancer, tumor location, size, and Hp infection, except 
for stages IA+IB. This suggests that E- cadherin may play 
a critical part in the early- stage tumorigenesis of EOGC 
[26]. However, we also reported that absent E- cadherin 
expression was associated with lower LVI rate compared 
to aberrant and normal group. This phenomenon may 
be explained by mesenchymal to epithelium transition 
(MET)[27]. E- cadherin is important in cellular junction 
and maintenance of epithelial phenotype. When E- cadherin 
switched to N- cadherin, epithelial–mesenchymal transition 
Table 2. Univariate and Multivariate Analyses (Cox Regression) on Prognosis of Early- onset gastric cancer Patients.
Factors Univariate analysis Multivariate analysis
RR (95% CI) P RR(95% CI) P
Female 1.340 (0.727–2.470) 0.348
Age 1.001 (0.950–1.055) 0.713
Positive Family history 0.769 (0.366–1.617) 0.489
Higher CA 72–4 3.185 (1.473–6.886) 0.003 4.622 (1.487–14.369) 0.008
Higher CA 125 3.701 (1.486–9.216) 0.005
Higher CA 19–9 4.241 (2.016–8.918) <0.001
Larger Tumor size (cm) 1.430 (1.295–1.580) <0.001 1.139 (1.000–1.296) 0.05
Positive resection Margin 5.617 (2.831–11.143) <0.001 5.718 (1.797–18.189) 0.003
Lymphovascular invasion 7.556 (2.960–19.288) <0.001
Perineural invasion 6.629 (2.583–17.013) <0.001
Staging I
II 2.722 (0.283–26.221) 0.386
III 22.488 (3.053–165.661) 0.002
IV 69.400 (8.597–560.260) <0.001 20.119 (1.486–272.465) 0.024
E- cadherin expression 1.018 (0.701–1.480) 0.924
ERα expression 1.230 (0.682–2.216) 0.492
ERβ expression 1.854 (0.663–5.185) 0.239
P53 expression 2.269 (1.262–4.077) 0.006
RR, relative risk; CI, confidence interval.
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(EMT) happens. After tumor cells spread to targeted region, 
disseminated tumor cells undergo MET. E- cadherin is 
regulated by both transcriptional and epigenetic mecha-
nism. As our study was limited to the protein level of 
E- cadherin expression, further analysis at gene levels and 
epigenetic level may help reveal the molecular pathogenesis 
mechanisms for E- cadherin in a large sample Chinese 
EOGC cases [28].
p53 is one of the most important genes that are mutated 
in gastric cancer [29, 30]. In accordance with the previous 
reports [31], patients with p53- positive and HIF- 1α- positive 
gastric cancer have worse prognosis, compared with those 
with double negative cancers. Our study on EOGC further 
suggests that p53- negative patients have a significantly better 
outcome than p53- positive patients, which is in disagree-
ment with a most recent Turkish report because of the 
different study population and a high percentage of elderly 
patients investigated [32]. We show that overexpression of 
p53 is associated with younger age but advanced stage of 
EOGC, suggestive of an aggressive biology behavior. And 
positive expression was associated with worse prognosis. 
However, multivariate analysis suggested it was not an inde-
pendent factor. A recently one study [33] from Korean 
reported that overexpression of p53 is less frequent in younger 
GC patients. The inconsistency may be explained by the 
selection of patients. We did not include older GC patients 
who are reported to have a high p53 mutation rate [9].
Relative to old gastric cancer patients, young patients 
have a female preponderance, a more frequent occurrence 
of the diffuse- type cancer, and less intestinal metaplasia 
[4, 24, 34]. This female gender predominance in EOGC 
is considered to be related to hormonal factors [35, 36]. 
While our results show an absence of a significant cor-
relation between ERα expression and clinicopathologic 
parameters, ERβ expression is indeed correlated with 
younger age and advanced cancer stages. In conventional 
gastric cancer with a high proportion of elderly patients, 
expression of ERα correlates with poor overall survival, 
as an independent predictor of overall survival [20], which 
is not confirmed in EOGC, suggesting different 
Table 3. Correlations among expression of E- cadherin, ERα, ERβ, and 
P53 in gastric cancer and adjacent nontumor tissue.
Correlation r1 P value2
E- cad (T) vs. E- cad (NT) 0.261 0.002
ERα (T) vs. ERα (NT) 0.051 0.554
ERβ (T) vs. ERβ (NT) 0.022 0.798
P53 (T) vs. P53 (NT) −0.03 0.722
ERα (T) vs. ERβ (T) −0.046 0.591
E- cad, E- cadherin.
1Spearman rank correlation coefficients
2Spearman rank correlation test.
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pathogenesis mechanisms between conventional gastric 
cancer and EOGC. Matsuyama et al. [19] reported that 
among signet ring carcinoma, ERβ cytoplasm was stained 
in addition to nuclei, especially in EOGC, which is exactly 
what we observed in this study. The exact role of cyto-
plasmic ERβ remains unclear, but because low expression 
level of ERα, we can conclude that ERβ may mediate 
the estrogen effect in stomach [37].
A major limitation of our study is that we focused on 
only protein alterations of E- cadherin, ERα, ERβ, and p53 
in EOGC. Therefore, the results remain to be validated by 
further investigations of genetic mutations of EOGC at DNA 
and RNA levels. Many EOGC patients diagnosed at advanced 
stages with extensive metastasis were excluded because of 
palliative management without surgery. The current results 
may be biased, which remain to be corrected in the upcom-
ing investigation of familiar gastric cancer.
In conclusion, our study demonstrated significant dif-
ferences in expression of E- cadherin, estrogen receptors, 
and p53 between EOGC tumors and adjacent uninvolved 
mucosal tissues. Expression of E- cadherin was significantly 
associated with the diffuse- type familial EOGCs and early 
stage, whereas expression of ERα might have little role 
in EOGC tumorigenesis. Expression of ERβ and p53 sig-
nificantly correlated with age and advanced cancer stages, 
and the p53- negative EOGC was associated with favorable 
outcomes. Further studies are needed to explore the dif-
ferent molecule genetic profile of EOGC from that of 
conventional gastric cancer occurring at a later age.
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